The proposed EU-U.S. trade agreement is set to impose a 15% levy on branded pharmaceuticals, potentially costing the industry $13 billion to $19 billion in added expenses. Analysts warn of significant financial impacts if exemptions are not granted, with the pharmaceutical sector being the largest casualty of the tariff expansion. Companies like Sanofi and Roche are taking proactive measures, such as selling production plants and stockpiling inventories, to mitigate the impact of the tariffs. Uncertainty remains around exemptions for generics and the timeline for finalizing the agreement, leaving the industry in regulatory limbo. The final text of the pact will be crucial for investors and policymakers seeking to restore duty-free access and avoid higher drug prices for consumers.

Read more at Quiver Quantitative LLC.: EU-U.S. Trade Deal Threatens $19B in Pharma Costs as New Tariffs Bite